Agilent Technologies, Inc. (A) vs Alnylam Pharmaceuticals, Inc. (ALNY)
A side-by-side comparison of Agilent Technologies, Inc. and Alnylam Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 3, 2026. Differences are shown without an overall score or investment verdict.
A
Agilent Technologies, Inc.
$149.93HealthcareDelayed quote: Sep 3, 2026, 12:55 PM EDT
ALNY
Alnylam Pharmaceuticals, Inc.
$264.30HealthcareDelayed quote: Sep 3, 2026, 12:55 PM EDT
Total return — A vs ALNY
growth of $100 · dividends reinvested · last 10yA +247.2% (+13.3%/yr)ALNY +268.7% (+13.9%/yr)ALNY compounded faster over this window
A ALNY
A vs ALNY: by the numbers
- •A is the larger company ($42.35B vs $35.37B market cap).
- •A trades at the lower trailing earnings multiple (29.80 vs 45.17 P/E), one valuation lens rather than an overall verdict.
- •A converts more revenue to profit (19.53% vs 16.82% net margin).
- •ALNY grew revenue faster over the past five years (47.53% vs 3.72% CAGR).
- •A pays a dividend (0.67% yield), while ALNY has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | A | ALNY |
|---|---|---|
| P/E ratio | 29.80 | 45.17 |
| Forward P/E | 24.41 | 39.80 |
| P/S ratio | 5.81 | 7.69 |
| P/B ratio | 5.82 | 27.30 |
| EV / EBITDA | 23.58 | 34.65 |
| FCF yield | 3.35% | 1.47% |
Profitability
| Metric | A | ALNY |
|---|---|---|
| Gross margin | 53.73% | 79.72% |
| Operating margin | 22.23% | 20.81% |
| Net margin | 19.53% | 16.82% |
| ROE | 19.56% | 59.67% |
| ROIC | 11.88% | 24.71% |
Dividends
| Metric | A | ALNY |
|---|---|---|
| Dividend yield | 0.67% | N/A |
| Payout ratio | 22.07% | N/A |
Growth (annualized)
| Metric | A | ALNY |
|---|---|---|
| Revenue CAGR (5Y) | 3.72% | 47.53% |
| EPS CAGR (5Y) | 14.52% | N/A |
| FCF CAGR (5Y) | 2.54% | N/A |
| Total return CAGR (5Y) | -2.50% | 5.96% |
Frequently asked
- Which has the lower trailing P/E, A or ALNY?
- A has the lower trailing P/E: A trades at 29.80 and ALNY at 45.17. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, A or ALNY?
- Over the past five years, ALNY grew revenue faster — A at a 3.72% CAGR versus ALNY at 47.53%.
- Does A or ALNY pay a bigger dividend?
- A pays a dividend (0.67% yield), while ALNY has no payments in the available dividend history.
- Is A or ALNY more profitable?
- A runs the higher net margin — A at 19.53% versus ALNY at 16.82%.
- How have A and ALNY total returns compared?
- Over the past 10 years, A delivered 13.29% and ALNY delivered 14.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Agilent Technologies P/E ratioAlnylam Pharmaceuticals P/E ratioAgilent Technologies dividend yieldAgilent Technologies ROEAlnylam Pharmaceuticals ROEAgilent Technologies operating marginAlnylam Pharmaceuticals operating marginAgilent Technologies revenue growthAlnylam Pharmaceuticals revenue growthAgilent Technologies free cash flowAlnylam Pharmaceuticals free cash flow
Agilent Technologies & Alnylam Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 3, 2026.